# Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

> **NCT03122548** · PHASE2 · TERMINATED · sponsor: **Aduro Biotech, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** CRS-207
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03122548
- **Lead sponsor:** Aduro Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-14
- **Primary completion:** 2017-12-27
- **Final completion:** 2018-01-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low enrollment and lack of clinical activity in other CRS-207 studies.
- **Last updated:** 2019-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122548, "Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03122548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*